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The present study was aimed at characterizing the mechanisms by which neurotensin
(NT) is acting within the ventral midbrain to induce a psychostimulant-like effect. In
a first experiment, we determine which subtype(s) of NT receptors is/are involved
in the reward-inducing effect of ventral midbrain microinjection of NT using the
conditioned place-preference (CPP) paradigm. In a second study, we used in vitro
patch clamp recording technique to characterize the NT receptor subtype(s) involved
in the modulation of glutamatergic neurotransmission (excitatory post-synaptic current,
EPSC) in ventral tegmental neurons that expressed (I+), or do not express (I−), ah h
hyperpolarization-activated cationic current. Behavioral studies were performed with
adult male Long-Evans rats while electrophysiological recordings were obtained from
brain slices of rat pups aged between 14 and 21 days. Results show that bilateral
ventral midbrain microinjections of 1.5 and 3 nmol of D-Tyr[11]NT induced a CPP
that was respectively attenuated or blocked by co-injection with 1.2 nmol of the
NTS1/NTS2 antagonist, SR142948, and the preferred NTS1 antagonist, SR48692. In
electrophysiological experiments, D-Tyr[11]NT (0.01-0.5µM) attenuated glutamatergic
EPSC in I+ but enhanced it in I− neurons. The attenuation effect (I+ neurons) was blockedh h h
by SR142948 (0.1µM) while the enhancement effect (I− neurons) was blocked by bothh
antagonists (0.1µM). These findings suggest that (i) NT is acting on ventral midbrain
NTS1 receptors to induce a rewarding effect and (ii) that this psychostimulant-like effect
could be due to a direct action of NT on dopamine neurons and/or an enhancement of
glutamatergic inputs to non-dopamine (I−) neurons.h
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INTRODUCTION
Neurotensin (NT), a tridecapeptide (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-
OH) isolated from the hypothalamus more than four decades ago (Carraway and Leeman, 1973),
acts as a potent modulator of limbic neurotransmission. Cell bodies and terminals that express
NT-like immunoreactivity are found in several limbic brain regions including the amygdala,
the nucleus accumbens, the prefrontal cortex, the septum, and the ventral midbrain (Jennes
et al., 1982; Hökfelt et al., 1984; Woulfe and Beaudet, 1989; Delle Donne et al., 1996). When
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released from nerve terminals, NT can activate three receptor
sub-types, NTS1, NTS2, and NTS3 (see Vincent et al., 1999).
The NTS1 and NTS2 are metabotropic receptors that are
coupled to G-proteins linked to different signaling pathways
such as cyclic guanosine-monophosphate, phospholipase C and
mitogen-activated protein kinase. The NTS3 is a non G- protein
coupled receptor that possesses a single transmembrane domain;
this receptor appears to be non-selective for NT as its binds
several other endogenous ligands (see Mazella and Vincent,
2006). The great majority of the central effects of NT have
been attributed to its action on either NTS1 or NTS2 receptors.
When administered into the lateral ventricle, for instance,
NT produces a dose-dependent hypothermia and analgesia
that are prevented by the NTS1/NTS2 antagonist, SR142948,
but not the preferred NTS1 antagonist, SR48692, suggesting
that they are mediated by the NTS2 receptor (Gully et al.,
1997). Central NT injections also attenuate spontaneous and
methamphetamine-induced locomotor activity, effects that are
prevented by SR48692 suggesting that they are mediated by
the NTS1 receptor (Wagstaff et al., 1994; Gully et al., 1995).
The behavioral effects of NT are not only dependent upon
the receptor sub-type that is activated but also upon the site
of action of the peptide within the limbic system. In the
ventral midbrain, for instance, NT stimulates dopamine impulse
flow and dopamine-dependent behaviors (Kalivas et al., 1981;
Holmes and Wise, 1985; Rompré et al., 1992) while in the
ventral striatum and the prefrontal cortex, it reduces the post-
synaptic effect of dopamine and attenuates dopamine-dependent
behaviors (Ervin et al., 1981; Kalivas et al., 1984; Béauregard et al.,
1992; Stowe et al., 2005). These findings led to the hypothesis
that NT may act as either an endogenous antipsychotic- or
psychostimulant-like neuromodulator (Bérod and Rostène, 2002;
Kinkead and Nemeroff, 2002). The mechanisms by which
NT produces psychostimulant-like effects remain imprecise.
The main hypothesis is that NT enhances dopamine release
and dopamine-dependent behaviors by stimulating dopamine
impulse flow through activation of NTS1 receptors expressed
on dopamine cell bodies and dendrites (see Bérod and Rostène,
2002). Consistently, NT induces an increase in dopamine inward
current and firing rate that is prevented by SR48692 (St-
Gelais et al., 2006). Activation of NTS1 receptors expressed on
dopamine neurons also inactivates the dopamine auto-receptor
which contributes to enhance dopamine impulse flow (Thibault
et al., 2011). We, and others, also reported that NT and its C-
terminal fragment, NT-(8-13), enhance excitatory post-synaptic
currents (EPSCs) in presumed dopamine neurons, an effect that
is blocked by SR48692 (Kempadoo et al., 2013; Bose et al., 2015).
Unexpectedly, the increase in ventral striatal dopamine release
induced by ventral midbrain application of NT is blocked by
SR142948 but not by SR48692 (Steinberg et al., 1994; Leonetti
et al., 2002) suggesting that NT is rather stimulating dopamine
impulse flow through activation of NTS2 receptors. This latter
finding, however, was not supported by another study showing
that application of ventral midbrain NT enhances ventral striatal
dopamine release in NTS2 but not NTS1 knock-out mice
(Leonetti et al., 2004). Neurotensin structure-activity studies
have also generated conflicting results regarding the role of
NTS1 receptors in the psychostimulant-like effect of NT. For
example, the enhancement effect of NT on locomotor activity
and on brain stimulation reward is mimicked by NT-(8-13)
and neuromedin N (Kalivas and Taylor, 1985; Kalivas et al.,
1986; Rompré and Gratton, 1992, 1993), two peptides that bind
and activate the NTS1 receptor (Kitabgi et al., 1980; Tanaka
et al., 1990). But the induction of a conditioned place-preference
(CPP) by repeated ventral midbrain NT microinjections is not
mimicked by an equimolar concentration of NT-(8-13); in fact
it is mimicked by a NT fragment, NT-(1-11), that fails to
interact with the NTS1 receptor (Kitabgi et al., 1980; Glimcher
et al., 1984); these results suggest that the conditioned rewarding
effect of NT may be mediated by a NT receptor other than
NTS1 receptor. In order to clarify this issue, we attempted to
determine which ventral midbrain NT receptor is involved in
the induction of a CPP using the NT analog, [D-Tyr11]NT
and the NT receptor antagonists, SR142948 and SR48692.
[D-Tyr11]NT mimicks several behavioral and neurochemical
effects of NT. When administered into the cerebral ventricle,
for instance, NT and [D-Tyr11]NT enhances brain stimulation
reward (Rompré, 1995; Bauco and Rompré, 2001) and sensitizes
to the locomotor activating effect of amphetamine (Rompré,
1997). Ventral midbrain infusion of NT and [D-Tyr11]NT
stimulates locomotor activity (Bauco and Rompré, 2003) and
enhances mesoaccumbens DA release (Steinberg et al., 1995;
Sotty et al., 2000). But, when injected unilaterally, [D-Tyr11]NT
is more effective than NT at inducing circling behavior (Steinberg
et al., 1995) and less effective at enhancing mesoprefontal DA
release (Sotty et al., 2000). These findings are consistent with
previous results showing than [D-Tyr11]NT is a NT agonist
that may preferentially activates one sub-type of NT receptors
(Kitabgi et al., 1980; Labbé-Jullié et al., 1994); it thus constitutes
an useful pharmacological tool to sort out the role of each of
these receptors in behavior. Because NT and NT-(8-13) also
enhance ventral midbrain glutamatergic neurotransmission, we
characterized the effect of [D-Tyr11]NT on glutamatergic EPSCs
in putative ventral midbrain dopamine and non-dopamine
neurons; the two populations were distinguished by the presence,
or the absence, of a hyperpolarization-activated cationic current
(Margolis et al., 2006) using the patch clamp recording technique.
Results of the behavioral experiments show that [D-Tyr11]NT
induced a dose-dependent CPP that was blocked by SR48692 and
attenuated by SR142948, suggesting that it is mediated by NTS1
receptors. Electrophysiological results show that [D-Tyr11]NT
dose-dependently attenuates glutamatergic EPSCs in putative
dopamine neurons while it enhances the EPSCs amplitude in
non-dopamine neurons; these effects are likely mediated by a
respective activation of NTS2 and NTS1 receptors.
MATERIALS AND METHODS
Behavioral Experiments
Animals
Male Long-Evans rats (Charles River, St-Constant, Qc, Canada)
weighing 280–320 g at the time of surgery were used. They
were housed 1 (after surgery) or 2 per cage in a temperature
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(22 ± 1◦C) and humidity (40–50%) controlled room with a
12 h light/dark cycle (lights on 06:00); standard rat chow and
water were available ad libitum. All testing was performed during
the light phase of the light–dark cycle. All animal experimental
procedures were approved by the Institutional Animal Ethics
Committee (Comité de déontologie de l’expérimentation sur les
animaux de l’Université de Montréal), in accordance with the
Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (n◦: 85–23, revised 1996).
All efforts were made to minimize the suffering and number of
animals used.
Surgery
Following 1 week habituation period to the colony room, each
rat was anesthetized with isoflurane (2.5–3.5%, 0.75 L/min
O2); solutions of 0.1ml of Anafen (5mg/kg, s.c.) and 0.05ml
(i.m.) of duplocillin LA containing 15,000 I.U. of penicillin
were administered to prevent inflammation and infection. The
animals was thenmounted on a stereotaxic apparatus, the surface
of the skull was exposed and a guide cannula (Model C315G,
Plastic One, VA, USA,) was implanted in each hemisphere, above
the ventral tegmental area (VTA), using the following stereotaxic
coordinates: 5.5mm posterior to bregma, 1.7mm lateral and
6.3mm below the surface of the cranium (Paxinos and Watson,
1986); cannulae were inserted into the brain with a mediolateral
angle of 8◦ and were closed with an obturator of the same
length. Four stainless-steel screws were threaded into the bone
and the cannulae were anchored to the skull with dental acrylic.
Behavioral tests started 1 week after the surgery.
Conditioned Place Preference (CPP) Paradigm
The CPP apparatus (Med Associates, St. Albans, VT, USA)
consisted of a rectangular Plexiglas box divided into two large
compartments (26 × 21 × 21 cm) separated by a smaller central
compartment (21 × 12 × 21 cm). Two sliding doors separated
the central gray compartment from the two others which have
distinct wall colors (white or black) and floors (grid or bar).
Locomotor activity and times spent in each chamber were
measured by computer-interfaced infrared photobeams (Med
Associates, St. Albans, VT, USA). The CPP experiment lasted 10
days and consisted of a habituation phase, a conditioning phase
and a test phase. On the first day of the habituation phase, rats
were allowed to explore the entire CPP apparatus for 20-min
to reduce neophobia. On day 2, all animals received a first
intra-VTA injection of 0.5µl/side of saline and were allowed to
explore freely the entire CPP apparatus for 20-min. On the third
day, animals were allowed to explore the entire CPP apparatus
for 20-min and time spent in each of the two large compartments
was measured; rats exhibiting higher or lower time interval than
20–80% of time in a compartment were excluded (unbiased
procedure). Conditioning began the next day. Conditioning
trials lasted 30-min and were conducted daily for 6 days. Control
and drug treatment groups were conditioned in either the
black or the white compartment of the apparatus. On the first
day of the conditioning phase, the drug-conditioned animals
were injected in the VTA with vehicle and were immediately
placed into one compartment of the apparatus for 30min.
The next day, animals were injected with [D-Tyr11]NT (1.5
or 3 nmol/0.5µl/side), SR142948 (1.2 nmol/0.5µl/side),
SR48692 (1.2 nmol/0.5µl/side), [D-Tyr11]NT
(3 nmol/0.5µl/side) + SR142948 (1.2 nmol/0.5µl/side) or [D-
Tyr11]NT (3 nmol/0.5µl/side) + SR48692 (1.2 nmol/0.5µl/side)
and were immediately placed into the other compartment of
the apparatus for 30min. This procedure was repeated three
times so that rats received three vehicle (Day 4, 6, and 8) and
three drug (Day 5, 7, and 9) injections. Animals in the control
group were injected with the vehicle on each day and were
similarly conditioned for 6 days. Twenty four hours after the
last day of the conditioning phase, on day 10, animals were
allowed to explore the apparatus for 20min and the time spent in
each compartment was measured. Animals were tested between
11:00 and 17:00 under an ambient light intensity of 5 lux and
were habituated to the experimental room for 1-h prior to the
behavioral testing.
Microinjection Procedure
Bilateral microinjections were made by inserting into each guide
cannula an injection cannula (model C315I) that extended 2mm
beyond the tip of the guide. Each cannula was connected with
polyethylene tubing to a 2-µl microsyringe and a volume of 0.5µl
of solution was injected into each hemisphere simultaneously
with a micro-infusion pump over a period of 60 s; cannulae were
left in place for an additional 60 s to allow diffusion into the
surrounding brain tissue.
Histology
At the end of the experiment, animals were deeply anesthetized
with urethane (2 g/kg, i.p.) and transcardially perfused with 0.9%
saline followed by 10% formalin. Brains were removed, stored in
10% formalin and subsequently sliced in serial 40-µm sections
that were stained with formal-thionin solution. Locations of
the injection sites were determined under light microscopic
examination. Only animals that had both injection sites within
the VTA, including the rostral and caudal linear nuclei, the
paranigral, parabrachial, and the interfascicular nuclei between
5.0 and 6.0mm behind bregma (Paxinos andWatson, 1986) were
included in the analyses.
Drugs
[D-Tyr11]neurotensin-(1-13) was purchased from Bachem
(Sunnydale, CA, USA) and dissolved in sterile 0.9% saline at a
concentration of 3 or 6 nmol/µl. The neurotensin antagonist,
SR-142948 and SR-48692 were purchased from Tocris Bioscience
(Burlington, ON, Canada) and were dissolved at a concentration
of 2.4 nmol/µl in a sterile 0.9% sodium chloride solution that
contained 20% dimethylsufoxyde (DMSO). All solutions were
stored at −20◦C in 50µl aliquots in silicone-coated tubes; they
were thawed just before testing and were used only once.
Statistical Analysis
Preference score was determined by subtracting the time
spent in the drug-paired compartment measured before
the conditioning phase (Pre) to the time spent in the
same compartment measured on the conditioning test day
(Post). Preference score and locomotor activity (horizontal
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and stereotypic-like movements) measured during the
conditioning test day were analyzed with a One-way analysis
of variance (ANOVA). The Duncan’s multiple range post-
hoc tests was used for individual group comparisons. The
accepted value for significance was set at 0.05 (Statistica V5.0,
StatSoft).
Electrophysiological Experiments
Animals and Slice Preparation
Fourteen to 21-day-old (P14-P21) Long Evans pups of either
sex obtained from Charles River (St-Constant, QC) were used.
Pups were anesthetized by methoxyflurane vapor inhalation in
a closed chamber, decapitated and their brain quickly removed
and transferred to chilled, oxygenated artificial cerebrospinal
fluid (ACSF) in which NaCl had been replaced by equivalent
osmolarity of sucrose and containing (in mM) sucrose 252 (NaCl
126 in standard ACSF); KCl, 3; NaH2PO4, 1.25; MgSO4 7 H2O,
1.3; CaCl2, 2.5; NaHCO3, 26; and glucose, 10, and saturated with
a gas mixture of 95% O2 and 5% CO2. Two hundred and fifty
micrometer thick horizontal slices preserving the VTA afferents
(Margolis et al., 2006) were cut using a vibratingmicrotome (DSK
Microslicer). Slices were transferred to a submerged recording
chamber maintained between 32 and 34◦C and superfused with
standard ACSF at a rate of 2ml/min; slices were incubated for at
least 1 h before recording began.
Electrophysiological Recordings
Whole-cell configuration was achieved using the “blind” patch-
clamp technique (Blanton et al., 1989). Pipettes were pulled from
thin wall borosilicate capillary glass on a P-87 micropipette puller
(Sutter Instrument, Novato, CA, USA). Recording pipettes had
a resistance of 3–5 M when filled with a solution containing
(in mM) potassium gluconate, 140; MgCl2, 2; CaCl2, 0.1; EGTA,
1.1; HEPES, 10; K2-adenosine trisphosphate (ATP), 2; guanosine
trisphosphate (GTP), 0.5 and biocytin (5%). The pHwas adjusted
to 7.3 with KOH solution, and final osmolarity was 280 ± 5
mosmol/kg. Biocytin (5%) was added in the recording pipette and
all recorded cells were processed after recording to confirm their
location in the medial VTA.
Whole-cell recordings were made with an Axoclamp
2B amplifier (Molecular Devices, Sunnyvale, CA, USA) in
continuous single-electrode voltage-clamp mode. The output
of the amplifier was fed into a LPF 200A DC amplifier/filter
(Warner Instruments Corp., Hamden, CT, USA) and digitized at
5–10 kHz with a real-time acquisition system (CED 1401 Power).
Data acquisition was achieved using the Signal 4.0 software
(Cambridge Electronic Design, Cambridge, England). Recording
pipette’s capacitance was optimally adjusted before whole-cell
configuration was achieved. The resting membrane potential
was measured just after rupturing the cell membrane and the
offset potential, measured upon withdrawal of the electrode
from the cell, was accounted for assuming that it drifted in a
linear fashion with time from the start of the recording session.
We did not correct for liquid junction potential which for a
pipette containing 140mM potassium gluconate amounts for an
additional potential shift of around −10mV (Spigelman et al.,
1992).
Synaptic Activation and Drug Application
The presence of Ih current was determined by voltage
clamping cells at −60mV and stepping to −40, −50,
−70,−80, −90, −100, −110, and −120mV. Input resistance
was monitored with hyperpolarizing pulses in current clamp
mode. A monopolar tungsten stimulating microelectrode was
placed rostral to the recording site in the medial VTA, on the
slice superficial layer, 0.5–1.0mm from the recording electrode.
Excitatory postsynaptic currents were evoked by 0.1ms, 3–6V
cathodal pulses delivered at 15 sec intervals. In order to isolate
glutamate receptor-mediated EPSCs, all experiments were
performed in the presence of (−) bicuculline methiodide (BMI,
10µM) in bath solution to block GABAA receptor-mediated
synaptic currents. BMI was applied 30min before obtaining
whole-cell configuration to ensure a complete diffusion in the
slice tissue. In all experiments the EPSCs were recorded from an
online voltage-clamped potential of −70mV. The effects of D-
Tyr [11] NT on glutamatergic EPSCs were assessed at a holding
membrane potential of −70mV. Three concentrations of the
peptide (0.01, 0.1, and 0.5µM) were tested, one concentration
per cell. Upon agonist application, the change in amplitude of
the glutamatergic EPSC was measured. Five minutes of baseline
EPSC activity was recorded before superfusion with the peptide.
The EPSC amplitudes were recorded during 7min after the onset
of the peptide application and averaged over the last 5min. A
washout period of 15min was allowed before the amplitude of
the recovered EPSC was measured. In some experiments, the
control EPSC amplitude was measured for 4min before a NT
antagonist was added to the superfusion medium. SR142948
nor SR48692 produced any change in EPSC amplitude (n = 12;
data not shown); therefore in further experiments where NTS
receptor antagonists were used, SR142948 or SR48692 was added
to the superfusing medium for 7min and a control response was
measured in the presence of the antagonist.
Drugs and Peptides
The following pharmacological agents were applied through the
superfusing ACSF: (−) bicuculline methiodide obtained from
Sigma Aldrich (Oakville, Ontario, Canada); D-Tyr [11] NT
from Bachem (Sunnyvale, CA, USA); SR-48692 and SR1429482
obtained from Tocris Biosciences (Burlington, ON, Canada). All
drugs were made up as 10mM stock solutions in distilled water
and diluted with ACSF solution to final concentration just before
addition to the perfusion medium with the exception of SR48692
which was dissolved in DMSO (final concentration 0.1%) and
distilled water.
Data analysis
Data analysis was performed using Signal software (Cambridge
Electronic Design, Cambridge, England). The magnitude of
EPSC recorded after application of the peptide was expressed
as percent of baseline and group means were calculated for
drug condition. A One-way ANOVA was performed and
Duncan post-hoc test used to determine significant differences
between concentration or drug and peptide condition when
justified; level of significance was set at 0.05 (Statistica V5.0,
StatSoft).
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RESULTS
Behavioral Experiment
From the 86 rats that completed the experiment, 10 were
excluded from the analysis because the injection sites were
dorsal or anterior to the VTA, or because the sites (left and
right hemisphere) overlapped on the midline; an additional
rat was excluded because the injection sites could not be
located.
Ventral Midbrain Microinjection of
[D-Tyr11]NT Induced a Conditioned Place
Preference
Figure 1 illustrates the preference score (top panel) and
locomotor activity (middle and bottom panels) measured during
the conditioning test in different groups of rats that were
conditioned with the vehicle and one of two doses of [D-
Tyr11]NT. As can be seen, animals that were conditioned with
VTA [D-Tyr11]NT microinjections spent more time in the
peptide associated compartment than the animal conditioned
with VTA microinjections of the vehicle. The ANOVA yielded
a significant effect of treatment [F(2, 31) = 13.1, p < 0.001]
and post-hoc test showed that preference score of each [D-
Tyr11]NT group was significantly different than vehicle; although
the preference score for the group treated with the highest dose
was superior to that of the lower dose there was no significant
difference between the two doses (p > 0.05). In order to
determine whether the preference for the [D-Tyr11]NT-paired
compartment was in part related to a conditioned aversion
to the unpaired compartment, we compared the preference
score for this compartment and the neutral compartment
among the three groups. Animals that were injected with [D-
Tyr11]NT spent less time in the unpaired compartment on
the conditioned test day than those injected with the vehicle
(Figure 2, top panel) but the ANOVA yielded no significant
effect of treatment [F(2, 31) = 2.4, p > 0.05]. Moreover,
the animals conditioned with the high dose of [D-Tyr11]NT
spent slightly less time in the neutral compartment (Figure 2,
bottom panel) compared to the other groups but the difference
was not significant [F(2, 31) = 2.33, p > 0.05]. Altogether,
these results suggest that the reduction in the time spent in
the compartment non-associated with VTA [D-Tyr11]NT in the
conditioned groups was due to an increase in the amount of
time spent in the conditioned but not the neutral compartment,
hence confirming the occurrence of a conditioned preference
effect.
The overall locomotor activity (in the entire apparatus)
measured during the conditioned test did not differ between
groups suggesting that repeated exposure to VTA [D-Tyr11]NT
did not induce conditioned locomotor activity (Figure 1, middle
and bottom panels). The ANOVA performed on each measure
of activity, horizontal and stereotypy-like, yielded no significant
effect of treatment [horizontal activity, F(2, 31) = 0.63 p > 0.05;
stereotypy-like activity, F(2, 31) = 0.14, p > 0.05].
FIGURE 1 | Induction of a CPP by [D-Tyr11]NT. Top panel illustrates the
preference score measured on the test day for the animals that were injected
with 1.5 nmol (NT1.5, n = 6), 3 nmol (NT3, n = 13) of [D-Tyr11]NT or its vehicle
(VEH, n = 15). Preference score corresponds to the amount of time (in sec)
spent in the paired compartment on the test day minus the time spent at
baseline in the same compartment. Measures of locomotor activity recorded
during the preference test for the animals in each treatment group are
presented in the middle panel (horizontal) and bottom panel
(stereotypy-like). Asterisks indicate a statistical significant difference with VEH
(**p < 0.01; ***p < 0.001).
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FIGURE 2 | Mean preference score measured on the test day in the
unpaired (top panel) and neutral (bottom panel) compartment for the
animals that were injected with 1.5 nmol (NT1.5, n = 6), 3 nmol (NT3,
n = 13) of [D-Tyr11]NT or its vehicle (VEH, n = 15). Preference score
corresponds to the amount of time (in sec) spent in the unpaired or neutral
compartment on the test day minus the time spent at baseline in the same
compartment. See text for details.
[D-Tyr11]NT-Induced a Conditioned Place
Preference: Role of NTS1 Receptors
To determine which NT receptor is involved in the induction of
a CPP by VTA [D-Tyr11]NT, we compared the preference score
obtained from animals that were conditioned with vehicle and
[D-Tyr11]NT alone to that of animals conditioned with either
SR142948 with [D-Tyr11]NT or SR48692 with [D-Tyr11]NT,
or each NT antagonist alone. Results presented in Figure 3
(top panel) shows that SR48692 blocked the induction of a
CPP. The ANOVA yielded a significant effect of treatments
[F(5, 61) = 5.74, p < 0.001] and post-hoc test showed that the
preference score of the group injected with preferred NTS1
antagonist, SR48692, with [D-Tyr11]NT is not significantly
different than that of the vehicle injected animals but is
significantly different than that of the [D-Tyr11]NT alone injected
animals. The NTS1/NTS2 antagonist, SR142948, attenuated the
induction of a CPP. When administered alone during the
conditioning phase, the antagonists induced no conditioned
FIGURE 3 | Effects of SR142948 and SR48692 on [D-Tyr11]NT-induced
CPP. Top panel illustrates the preference score measured on the test day for
(Continued)
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FIGURE 3 | Continued
the animals that were injected with 3 nmol of [D-Tyr11]NT (NT, n = 13),
1.2 nmol of SR142948 (SR142, n = 10), 1.2 nmol of SR48692 (SR48, n = 7),
SR142948 + [D-Tyr11]NT (SR142+NT, n = 12), SR48292 + [D-Tyr11]NT
(SR48+NT, n = 10) or the vehicle (VEH, n = 15). Preference score
corresponds to the amount of time (in sec) spent in the paired compartment
on the test day minus the time spent at baseline in the same compartment.
Measures of locomotor activity recorded during the preference test for the
animals in each treatment group are presented in the middle panel
(horizontal) and bottom panel (stereotypy-like). The asterisks and the cross
indicate a statistical significant difference with VEH (*p < 0.01; ***p < 0.001)
and NT (+p < 0.05) respectively.
effect. Altogether, these results show that the conditioned
preference is due to activation of VTA NTS1 receptors.
Locomotor activity measured in the entire apparatus during the
conditioned test did not differ between groups [Figure 3, middle
and bottom panels; horizontal activity, F(5, 61) = 1.14, p > 0.05;
stereotypy-like activity, F(5, 61) = 0.93. p > 0.05].
ELECTROPHYSIOLOGICAL RESULTS
Whole-cell voltage-clamp recording was carried out on
96 physiologically identified VTA neurons. Neurons were
designated as I+h (n = 54) or I
−
h (n = 42) based on the presence
or absence of the hyperpolarization activated cationic current
(Ih). The amplitude of Ih in I
+
h positive neurons ranged from
67 pA to 419 pA with an average of 192.3 pA (n = 54; data not
shown).
Effects of D-Tyr [11] NT on Glutamatergic
EPSCs in I+h and I
−
h Neurons
The effects of [D-Tyr11]NT on glutamatergic EPSCs in VTA
neurons were measured at a holding membrane potential
of −70mV upon application at three different concentrations
(0.01, 0.1, and 0.5µM). Desensitization of the response to [D-
Tyr11]NT application allowed only one concentration of the
peptide to be tested per cell.
Representative traces of the evoked EPSCs from a single I+h
cell obtained before, during and after washout of 0.01µM of
[D-Tyr11]NT are shown in Figure 4. It can be seen that [D-
Tyr11]NT attenuated the EPSC and that this effect was completely
reversible. As shown in Figure 5 [D-Tyr11]NT produced a dose
dependent reduction in the amplitude of the glutamatergic
EPSCs in I+h cells. At concentrations of 0.01, 0.1, and 0.5µM,
the mean decrease in EPSC amplitude was 20 ± 1.5% (n = 6),
29 ± 3% (n = 6), and 47 ± 4% (n = 7) respectively. A One-
way ANOVA yielded significant effect [F(2, 16) = 20.95, p <
0.001] and post-hoc test confirmed that the highest concentration
produced a decrease that was significantly different than that
produced by the lower concentration (p < 0.001).
In I−h cells, [D-Tyr
11]NT produced a dose-dependent increase
in the amplitude of the evoked EPSC. Representative traces
obtained from a single I−h cell illustrated in Figure 6 show that
the enhancement effect of [D-Tyr11]NT was also reversible. The
mean increase at concentrations of 0.01, 0.1, and 0.5µM was
15 ± 2.5% (n = 6), 28 ± 2% (n = 6), and 56 ± 3.5% (n = 9)
respectively (Figure 5). A One-way ANOVA yielded significant
results [F(2, 18) = 51.7, p < 0.001]; post-hoc test showed that
there a significant different between the highest concentration
and the two others (p < 0.001), and between the medium and
the lowest concentration (p < 0.01).
Effect of NTS Antagonists in I+h and I
−
h
Neurons
To identify the neurotensin receptor subtype(s) involved in the
enhancement and attenuation effects of [D-Tyr11]NT on the
evoked EPSCs in each cell population, we measured the EPSCs in
the presence of SR142948 or SR48692. We found that in I+h cells,
SR48692 (0.5µM) and SR142948 (0.5µM) were both effective
at blocking the decrease in EPSC amplitude produced by [D-
Tyr11]NT (Figure 7, top panel). It can be noted that in the in
the presence of this high concentration of the antagonists, [D-
Tyr11]NT produced an enhancement of the EPSC amplitude.
A One way ANOVA yielded a significant effect [F(2, 11, 89.3) =
p < 0.001] and post-hoc test confirmed that the EPSCs measured
in the presence of the antagonist were significantly different than
the EPSCs measured in the presence of [D-Tyr11]NT alone; there
was also a significant difference between the effect of SR142948
and SR48692. Interestingly, different results were obtained when
the concentration of the antagonist was reduced to 0.1µM. At
this concentration, SR142948 blocked the attenuation effect of
[D-Tyr11]NT while SR48692 had no effect (Figures 4, 7). The
ANOVA yielded significant effect [F(2, 11)= 37.7, p < 0.001]
and post-hoc test confirmed that the mean EPSC measured in
the presence of SR142948 was significantly different than that
measured in the presence of [D-Tyr11]NT alone or SR48692 +
[D-Tyr11]NT.
In I−h cells, at the highest concentration (0.5µM), SR48692
and SR142948 blocked the enhancement effect of [D-Tyr11]NT
on the EPSC (Figure 7, bottom panel); in the presence of
SR142948, [D-Tyr11]NT produced a large attenuation of the
EPSC. The ANOVA yielded significant effect [F(2, 14)= 40.6,
p < 0.001] and post-hoc test showed that the EPSC measured
in the presence of SR142948 and SR48692 was significantly
different than that measured in the presence of [D-Tyr11]NT
alone. There was also a significant difference in EPSCs measured
in the presence of SR142948 and SR48692, confirming that
SR142948 led to a significant attenuation. Similarly to what we
observed in I+h cells, different results were obtained when the
concentration of the antagonists was reduced to 0.1µM. At
this concentration, SR142948 and SR48692 similarly blocked the
enhancement effect of [D-Tyr11]NT (Figures 6, 7). The ANOVA
yielded significant effect [F(2, 13)= 18.5, p < 0.001] and post-hoc
test confirmed that the mean EPSC measured in the presence
of SR142948 and SR48692 were not different but were both
different than that measured in the presence of [D-Tyr11]NT
alone.
DISCUSSION
The main finding of this study is that activation of
ventral midbrain NTS1 receptor induces a CPP and that
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FIGURE 4 | Effect of [D-Tyr11]NT and antagonists on I+
h
neurons. Panel 1: Current traces of glutamatergic EPSC recorded during superfusion of [D-Tyr11]NT;
control (1), with [D-Tyr11]NT (0.01µM) (2) and following the washout of [D-Tyr11]NT (3) at a holding membrane potential of −70mV in I+h neurons (n = 6). Panel 2:
Current traces of glutamatergic EPSC recorded during superfusion with SR142948 (0.1µM) (1), with SR142948 and [D-Tyr11]NT (0.01µM) (2) and with SR142948
following the washout of (3) at a holding membrane potential of −70mV in I+h neurons (n = 5). Panel 3: Current traces of glutamatergic EPSC recorded during
superfusion with SR48692 (0.1µM) (1), with SR48692 and [D-Tyr11]NT (0.01µM) (2) and with SR48692 following the washout of [D-Tyr11]NT (3) at a holding
membrane potential of −70mV in I+h neurons (n = 4).
this effect can be mediated, at least in part, through an
enhancement of glutamatergic synaptic input in non-
dopamine neurons in the VTA. Our results also show
that [D-Tyr11]NT activates NTS2 receptors to reduce
glutamatergic synaptic input to VTA dopamine and non-
dopamine neurons. To our knowledge these findings
constitute the first evidence that NT acts on two different
NT receptor sub-types to modulate in an opposite manner
glutamatergic neurotransmission in different populations of
VTA neurons.
Previous studies have shown that ventral midbrain NT
microinjection produces a rewarding effect as it sustains
self-administration (Glimcher et al., 1987), enhances brain
stimulation reward (Rompré et al., 1992) and induces a CPP
(Glimcher et al., 1984). Consistently, we found that ventral
midbrain microinjections of [D-Tyr11]NT dose-dependently
induced a preference for the environment associated with
the peptide. The induction of a CPP by [D-Tyr11]NT is
consistent with many other results showing that this NT analog
mimics several behavioral, physiological and neurochemical
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FIGURE 5 | Effects of [D-Tyr11]NT on glutamatergic EPSCs in I+
h
and I−
h
neurons. Mean percent change in EPSC amplitude recorded in I+h (black bar)
and I−h (white bar) following application of different concentrations of
[D-Tyr11]NT. The number of neurons recorded at each concentration is as
follow: 0.01µM, n = 12 (I+h n = 6, I
−
h n = 6); 0.1µM, n = 12 (I
+
h n = 6, I
−
h
n = 6); 0.5µM, n = 16 (I+h n = 7, I
−
h n = 9). All concentrations of D-Tyr[11]NT
are reported in µM. Asterisks indicate a statistically significant difference with
the lowest concentration (**p < 0.05; ***p < 0.001). See text for details.
effects of NT (Jolicoeur et al., 1984; Donoso et al., 1986; al-
Rodhan et al., 1991; Steinberg et al., 1995; Rompré, 1997).
According to Glimcher et al. (1984), however, the induction
of CPP by repeated ventral midbrain NT is not reproduced
by an equimolar concentration of NT-(8-13); such a result
was unexpected because NT-(8-13) displays a high affinity
for the NTS1 (Kitabgi et al., 1980) and has been shown to
be as effective as NT at inducing locomotor activity (Kalivas
and Taylor, 1985; Steinberg et al., 1995), enhancing brain
stimulation reward (Rompré and Gratton, 1993), increasing
dopamine cell firing (Seutin et al., 1989; Shi and Bunney,
1991) and inducing polydipsia (Hawkins et al., 1989). One
possible explanation is that Glimcher et al. (1984) compared the
effectiveness of bilateral VTAmicroinjections of NT to equimolar
unilateral microinjections of NT-(8-13); it could be that at the
concentration used unilateral microinjections were insufficient to
induce a CPP.
The induction of a CPP by [D-Tyr11] was blocked by SR48692
hence suggesting that it is mediated by NTS1 receptors. It has
been shown that activation of NTS1 receptors expressed on
dopamine neurons stimulates cell firing and dopamine release
in brain regions known to play a key role in reward (Woulfe
and Beaudet, 1989; Leonetti et al., 2004; St-Gelais et al., 2006;
Thibault et al., 2011). Kempadoo et al. (2013) also showed that
activation of VTA NTS1 receptors by local NT release reinforces
operant responding. Altogether, this suggests that the induction
of a CPP by [D-Tyr11]NT could be due to activation of NTS1
receptors expressed on VTA dopamine neurons. A role for NTS1
is in contradiction, however, with Glimcher et al’s results showing
a CPP is induced by repeated injections of NT-(1-11), a N-
terminal fragment that fails to interact with the NTS1 receptor
(Kitabgi et al., 1980). To our knowledge, no other studies have
reported NT-like effects following central injection of NT-(1-
11). That suggests that the conditioned rewarding effect of NT-
(1-11) is NT-independent. This hypothesis is reinforced by an
in vitro study reporting that NT-(1-11) dose-dependently inhibits
cortisol production in cultured adrenocortical cells, an effect that
is not reproduced by NT-(1-13) and not mediated by any of the
known NT receptors (Sicard et al., 2006).
Conditioned place-preference is a learning process that
involves neural plasticity. Drugs that induce a CPP, such
as cocaine and morphine, induce lasting changes in VTA
glutamatergic neurotransmission (Zweifel et al., 2008) and
blockade of VTA glutamatergic receptors prevents cocaine-
(Harris and Aston-Jones, 2003) and morphine-induced CPP
(Harris et al., 2004). Kempadoo et al. (2013) have also shown
that the rewarding effect of VTA NT release is associated
with an enhancement of glutamatergic input to dopamine
neurons. In order to determine whether the induction of a
conditioned reward by [D-Tyr11]NT was related to a modulation
of glutamatergic inputs to VTA neurons, we investigated the
effect of [D-Tyr11]NT on glutamatergic EPSCs in different
population of neurons distinguished with the presence or absence
of an Ih current. Nearly, all dopaminergic neurons express an Ih
current while I+h neurons represent a subset of non-dopaminergic
neurons; some GABA and glutamatergic neurons also express an
Ih current (Lacey et al., 1989; Johnson and North, 1992; Margolis
et al., 2006, 2012; Hnasko et al., 2012).
In the present study, we observed that bath application
of varying concentrations of [D-Tyr11]NT generated a dose-
dependent enhancement in the amplitude of glutamatergic
EPSCs in I−h neurons (non-dopamine neurons). This
enhancement was most likely mediated by activation of NTS1
receptors as it was blocked by SR142948 and SR48692. These
findings are in parallel with the behavioral results and suggest
the action of NT on glutamatergic inputs to non-dopamine
neurons may also play a key role in conditioned reward. Since
the VTA contains a high density of NT terminals, it is thus
possible that the effect of NT is not limited to glutamatergic
inputs to dopamine neurons in this region (Jennes et al., 1982;
Geisler and Zahm, 2006). Luo et al. (2010), for instance, showed
that cocaine still induces a CPP in animals that had selective
deletion of NMDA receptors onto dopamine neuron, and that
this conditioned rewarding effect was NMDA-dependent.
In several limbic regions such as in the entorhinal cortex
and the dentate gyrus of the hippocampus, activation of
NTS1 receptors induces an excitatory effect and an increase
in glutamate release (Rostène and Alexander, 1997; Antonelli
et al., 2007, 2008); these effects are dependent on coupling
to PLC, phosphokinase C (PKC) and Ca2+influx through L-
type Ca2+ channels and activation of myosin light chain
kinases respectively (Xiao et al., 2014; Zhang et al., 2015).
Additionally, evidence of a facilitatory NTS1-NMDA receptor
interaction at cortico-striatal glutamate terminals strengthens
the role of NT in modulating glutamate release (Antonelli
et al., 2004). Although, within the scope of our study,
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FIGURE 6 | Effect of [D-Tyr11]NT and antagonists on I−
h
neurons. Panel 1: Current traces of glutamatergic EPSC recorded during superfusion of [D-Tyr11]NT;
control (1), with [D-Tyr11]NT (0.01µM) (2) and following the washout of [D-Tyr11]NT (3) at a holding membrane potential of −70mV in I−h neurons (n = 6). Panel 2:
Current traces of glutamatergic EPSC recorded during superfusion with SR142948 (0.1µM) (1), with SR142948 and [D-Tyr11]NT (0.01µM) (2) and with SR142948
following the washout of [D-Tyr11]NT (3) at a holding membrane potential of −70mV in I−h neurons (n = 5). Panel 3: Current traces of glutamatergic EPSC recorded
during superfusion with SR48692 (0.1µM) (1), with SR48692 and [D-Tyr11]NT (0.01µM) (2) and with SR48692 following the washout of [D-Tyr11]NT (3) at a holding
membrane potential of −70mV in I−h neurons (n = 5).
we were not able to identify the exact effector molecules
mediating this action, association of NTS1 receptors to such
downstream excitatory signaling cascades might have come into
play.
When tested over the same range of concentrations,
[D-Tyr11]NT generated a dose-dependent attenuation in
the amplitude of glutamatergic EPSCs in I+h neurons. This
attenuation was most likely mediated by activation of NTS2
receptors as it was blocked by a low concentration of SR142948
but not SR48692. As mentioned previously, all VTA dopamine
neurons are I+h and that strongly suggests that [D-Tyr
11]NT
reduces glutamatergic inputs to at least a population of VTA
dopamine neurons. In view of the evidence of a role for
VTA dopamine in reward, and of the enhancement effect
of NT on VTA dopamine impulse flow, these results were
unexpected. They suggest that the action of [D-Tyr11]NT
on glutamatergic inputs to VTA dopamine neurons through
activation of NTS2 receptors is unlikely involved in the
induction of a conditioned reward. In fact, the action of
[D-Tyr11]NT on NTS2 should oppose its action on NTS1
and contribute to reduce its effectiveness at inducing a
conditioned reward. This may explain why SR142948 which
displays a similar affinity for NTS1 and NTS2 (Gully et al.,
1997) was less effective than SR48692, a preferred NTS1
antagonist (Gully et al., 1995), at attenuating the induction of
CPP.
There is also a large proportion of VTA GABA neurons
that express an Ih current and it has been shown that GABA
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FIGURE 7 | Effect of SR142948 and SR48692 on glutamatergic EPSCs
in I+
h
and I−
h
neurons. Mean percent change in EPSC amplitude recorded in
I+h (A) and I
−
h neurons (B) following application of [D-Tyr
11]NT alone or in the
presence of SR142948 or SR48692. The number of neurons recorded under
each condition is as follow: I+h neurons, [D-Tyr
11]NT (0.01µM, n = 6; 0.1µM,
n = 6); SR142948 (0.1µM, n = 5; 0.5µM, n = 4); SR48692 (0.1µM, n = 4;
0.5µM, n = 4); I−h neurons, [D-Tyr
11]NT (0.01µM, n = 6; 0.1µM, n = 6);
SR142948 (0.1µM, n = 5; 0.5µM, n = 5); SR48692 (0.1µM, n = 5; 0.5µM,
n = 4). All concentrations of D-Tyr[11]NT, SR142948, and SR48692 are
reported in µM. Asterisks and crosses indicate a statistically significant
(Continued)
FIGURE 7 | Continued
difference with [D-Tyr11]NT alone at 0.01µM and 0.1µM respectively
(***p < 0.001 with 0.01µM; +++p < 0.001 with 0.1µM). The ### sign
indicates a statistical significant difference between SR142948 (0.5µM)
+D-Tyr[11]NT (0.1µM) and SR48692 (0.5µM) +D-Tyr[11]NT (0.1µM). See
text for details.
provides an inhibitory drive to dopamine neurons that is under
the control of glutamate (Grace et al., 2007). An attenuation
of glutamatergic input to these neurones is likely to enhance
dopamine impulse flow resulting in reward and/or reward
enhancement. If [D-Tyr11] NT is acting on NTS2 receptors
to reduce glutamatergic EPSCs to these neurons, SR142948
would have been more effective than SR48692 at attenuating
the induction of CPP; but as mentioned above, we observed the
opposite.
The attenuation effect of [D-Tyr11]NT on glutamatergic
EPSCs in I+h neurons contrasts with the enhancement effect
of NT and NT-(8-13) reported in previous studies (Kempadoo
et al., 2013; Bose et al., 2015). Indeed both NT and NT-(8-13)
enhance glutamatergic EPSC in I+h neurons by activating
NTS1 receptors. Kempadoo et al. (2013), however, observed
a biphasic effect with NT-(8-13), an enhancement of NMDA
EPSCs at a low concentration and an attenuation at a high
concentration; the former but not the latter was blocked by
SR48692 suggesting that the attenuation is not mediated by
the NTS1 receptor. It thus appears that both NTS1 and NTS2
modulate glutamatergic inputs to I+h neurons and that [D-
Tyr11]NT has a predominant effect on the NTS2 receptor
subtype. [D-Tyr11]NT has a higher affinity for NTS2 than NTS1
(Kitabgi et al., 1980; Labbé-Jullié et al., 1994) and activation of
NTS2 receptors do not induce excitatory effects. For instance,
activation of human NTS2 receptors expressed on CHO cell
lines lacks the potential to elevate intracellular Ca2+ levels by
mobilizing internal calcium reserves or accumulation IP3; it
was rather associated with activation mitogen activated protein
kinases (MAPK) that led to inhibition (Sarret et al., 2002).
It could be that activation of NTS2 receptors on putative
dopamine neurons enhances MAPK signaling and produces
a reduction in glutamatergic signaling. Although there is no
evidence reported in the literature that [D-Tyr11]NT can
generate a NTS1- or NTS2-mediated biased signalization, it has
been recently reported that modified analogs of NT-(8-13) at
the 11 amino acid position displayed NTS1-mediated biased
activation of Gαq and β-arrestin signaling pathways (Fanelli et al.,
2015).
The 11th position substitution in [D-Tyr11]NT by a D-
tyrosine residue makes it more resistant to cleavage by
endopeptidases (Checler et al., 1983). In fact, after an
intracerebroventricular injection of NT, 98% of the NT was
cleared and degraded in brain tissues during a 30min period
after the injection. Under the same conditions, 33% of [D-
Tyr11]NT was retained, suggesting a half-life 1.5 times greater
than that of NT (Checler et al., 1983). Owing to the relatively
stable metabolic profile of [D-Tyr11]NT it is possible that the
reduction in EPSC observed by Kempadoo et al. (2013) with
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higher concentrations of NT8-13 reflects that produced by
the lower concentrations of [D-Tyr11]NT used in the present
study.
Interestingly, in the presence of a high concentration (0.5µM)
of SR142948, but not SR48692, [D-Tyr11]NT produced an
opposite, significant inhibition, of glutamatergic EPSCs in I−h
neurons. This could possibly arise because at this concentration,
SR142948 interacts with an NT receptor subtype other than
NTS1 and NTS2 (possibly NTS3). The NTS3 protein and
its mRNA are present in VTA and are mainly expressed on
cell bodies and dendrites. According to Mazella et al. (1998),
the NTS3 receptor is nearly insensitive to SR48692. Others,
however, reported that SR142948 is effective at blocking the
NTS3-mediated growth response to NT in cancer cells (Dal
Farra et al., 2001); that would rather exclude a role for this
receptor in the opposite effect of [D-Tyr11]NT on EPSC in the
presence of SR142948. In I+h neurons, the presence of a high
concentration of SR142948 and SR48692 had the same impact;
[D-Tyr11]NT enhanced the EPSC, an effect opposite to what was
observed when it was infused alone. As mentioned previously,
it remains unclear why the antagonists produce such a reverse
effect.
AUTHOR CONTRIBUTIONS
PR and KR designed the behavioral experiments; KR carried out
the behavioral experiments and analyzed the data with PR. RW
and PB designed the electrophysiological experiments; PB carried
out the electrophysiological experiments and analyzed the data
with RW and PR. All authors contributed and approved the final
version of the manuscript.
FUNDING
Funding for this study was provided by Canadian Institutes
of Health Research (Grant #102572 to PR and RW), Natural
Sciences and Engineering Research Council of Canada (Grant #
184095-2009 to RW) and Fonds de Recherche Santé Québec.
ACKNOWLEDGMENTS
The authors would like to thankClaude Bouchard for his support,
excellent expertise and sound advice; Dr Daniel Lévesque for his
relevant suggestions and comments; all the staff of the Pavillon
Paul-G Desmarais animal’s facility.
REFERENCES
al-Rodhan, N. R., Richelson, E., Gilbert, J. A., McCormick, D. J., Kanba, K. S.,
Pfenning, M. A., et al. (1991). Structure-antinociceptive activity of neurotensin
and some novel analogues in the periaqueductal gray region of the brainstem.
Brain Res. 557, 227–235.
Antonelli, T., Ferraro, L., Fuxe, K., Finetti, S., Fournier, J., Tanganelli, S.,
et al. (2004). Neurotensin enhances endogenous extracellular glutamate levels
in primary cultures of rat cortical neurons: involvement of neurotensin
receptor in NMDA induced excitotoxicity. Cereb. Cortex 14, 466–473. doi:
10.1093/cercor/bhh008
Antonelli, T., Fuxe, K., Tomasini, M. C., Mazzoni, E., Agnati, L. F.,
Tanganelli, S., et al. (2007). Neurotensin receptor mechanisms and
its modulation of glutamate transmission in the brain: relevance for
neurodegenerative diseases and their treatment. Prog. Neurobiol. 83, 92–109.
doi: 10.1016/j.pneurobio.2007.06.006
Antonelli, T., Tomasini, M. C., Fournier, J., Mazza, R., Tanganelli, S., Pirondi,
S., et al. (2008). Neurotensin receptor involvement in the rise of extracellular
glutamate levels and apoptotic nerve cell death in primary cortical cultures
after oxygen and glucose deprivation. Cereb. Cortex 18, 1748–1757. doi:
10.1093/cercor/bhm217
Bauco, P., and Rompré, P. P. (2001). Effects of neurotensin receptor activation on
brain stimulation reward in Fischer 344 and Lewis rats. Eur. J. Pharmacol. 432,
57–61. doi: 10.1016/S0014-2999(01)01466-2
Bauco, P., and Rompré, P. P. (2003). Central neurotensin receptor activation
produces differential behavioral responses in Fischer and Lewis rats.
Psychopharmacology (Berl.) 168, 253–261. doi: 10.1007/s00213-003-
1436-8
Béauregard, M., Ferron, A., and Descarries, L. (1992). Opposite effects
of neurotensin on dopamine inhibition in different regions of the rat
brain: an iontophoretic study. Neuroscience 47, 613–619. doi: 10.1016/0306-
4522(92)90170-7
Bérod, A., and Rostène, W. (2002). Neurotensin: an endogenous psychostimulant?
Curr. Opin. Pharmacol. 2, 93–98. doi: 10.1016/S1471-4892(01)00127-8
Blanton, M. G., Lo Turco, J. J., and Kriegstein, A. R. (1989). Whole cell recording
from neurons in slices of reptilian and mammalian cerebral cortex. J. Neurosci.
Methods 30, 203–210. doi: 10.1016/0165-0270(89)90131-3
Bose, P., Rompré, P., and Warren, R. A. (2015). Neurotensin enhances
glutamatergic EPSCs in VTA neurons by acting on different neurotensin
receptors. Peptides 73, 43–50. doi: 10.1016/j.peptides.2015.08.008
Carraway, R., and Leeman, S. E. (1973). The isolation of a new hypotensive peptide,
neurotensin, from bovine hypothalami. J. Biol. Chem. 248, 6854–6861.
Checler, F., Vincent, J. P., and Kitabgi, P. (1983). Neurotensin analogs [D-TYR11]
and [D-PHE11]neurotensin resist degradation by brain peptidases in vitro and
in vivo. J. Pharmacol. Exp. Ther. 227, 743–748.
Dal Farra, C., Sarret, P., Navarro, V., Botto, J. M., Mazella, J., and Vincent, J. P.
(2001). Involvement of the neurotensin receptor subtype NTR3 in the growth
effect of neurotensin on cancer cell lines. Int. J. Cancer 92, 503–509. doi:
10.1002/ijc.1225
Delle Donne, K. T., Sesack, S. R., and Pickel, V. M. (1996). Ultrastructural
immunocytochemical localization of neurotensin and the dopamine
D2 receptor in the rat nucleus accumbens. J. Comp. Neurol. 371,
552–566.
Donoso, M. V., Huidobro-Toro, J. P., and St-Pierre, P. S. (1986). Gastrointestinal
neurotensin receptors: contribution of the aromatic hydroxyl group in position
11 to peptide potency. Br. J. Pharmacol. 87, 483–485. doi: 10.1111/j.1476-
5381.1986.tb10189.x
Ervin, G. N., Birkemo, L. S., Nemeroff, C. B., and Prange, A. J. Jr. (1981).
Neurotensin blocks certain amphetamine-induced behaviours. Nature 291,
73–76.
Fanelli, R., Besserer-Offroy, É., René, A., Côté, J., Tétreault, P., Collerette-
Tremblay, J., et al. (2015). Synthesis and characterization in vitro and in vivo
of (l)-(Trimethylsilyl)alanine containing neurotensin analogues. J. Med. Chem.
58, 7785–7795. doi: 10.1021/acs.jmedchem.5b00841
Geisler, S., and Zahm, D. S. (2006). On the retention of neurotensin in the
ventral tegmental area (VTA) despite destruction of the main neurotensinergic
afferents of the VTA-implications for the organization of forebrain projections
to the VTA. Brain Res. 1087, 87–104. doi: 10.1016/j.brainres.2006.02.108
Glimcher, P. W., Giovino, A. A., and Hoebel, B. G. (1987). Neurotensin
self-injection in the ventral tegmental area. Brain Res. 403, 147–150. doi:
10.1016/0006-8993(87)90134-X
Glimcher, P. W., Margolin, D. H., Giovino, A. A., and Hoebel, B. G.
(1984). Neurotensin: a new ‘reward peptide’. Brain Res. 291, 119–124. doi:
10.1016/0006-8993(84)90657-7
Frontiers in Neuroscience | www.frontiersin.org 12 December 2015 | Volume 9 | Article 470
Rouibi et al. Neurotensin-Glutamate Interaction and Conditioned Reward
Grace, A. A., Floresco, S. B., Goto, Y., and Lodge, D. J. (2007). Regulation of
firing of dopaminergic neurons and control of goal-directed behaviors. Trends
Neurosci. 30, 220–227. doi: 10.1016/j.tins.2007.03.003
Gully, D., Jeanjean, F., Poncelet, M., Steinberg, R., Soubrié, P., Le Fur, F. G., et al.
(1995). Neuropharmacological profile of non-peptide neurotensin antagonists.
Fundam. Clin. Pharmacol. 9, 513–521. doi: 10.1111/j.1472-8206.1995.
tb00528.x
Gully, D., Labeeuw, B., Boigegrain, R., Oury-Donat, F., Bachy, A., Poncelet, M.,
et al. (1997). Biochemical and pharmacological activities of SR 142948A, a new
potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 280, 802–812.
Harris, G. C., and Aston-Jones, G. (2003). Critical role for ventral tegmental
glutamate in preference for a cocaine-conditioned environment.
Neuropsychopharmacology 28, 73–76. doi: 10.1038/sj.npp.1300011
Harris, G. C., Wimmer, M., Byrne, R., and Aston-Jones, G. (2004). Glutamate-
associated plasticity in the ventral tegmental area is necessary for conditioning
environmental stimuli with morphine. Neuroscience 129, 841–847. doi:
10.1016/j.neuroscience.2004.09.018
Hawkins, M. F., Baker, J. D., and Baumeister, A. A. (1989). Neurotensin-induced
polydipsia: a structure-activity study. Brain Res. 487, 188–191. doi: 10.1016/
0006-8993(89)90957-8
Hnasko, T. S., Hjelmstad, G. O., Fields, H. L., and Edwards, R. H. (2012).
Ventral tegmental area glutamate neurons: electrophysiological properties and
projections. J. Neurosci. 32, 15076–15085. doi: 10.1523/JNEUROSCI.3128-
12.2012
Hökfelt, T., Everitt, B. J., Theodorsson-Norheim, E., and Goldstein, M.
(1984). Occurrence of neurotensinlike immunoreactivity in subpopulations of
hypothalamic, mesencephalic, and medullary catecholamine neurons. J. Comp.
Neurol. 222, 543–559. doi: 10.1002/cne.902220407
Holmes, L. J., and Wise, R. A. (1985). Dopamine-dependent contralateral circling
induced by neurotensin applied unilaterally to the ventral tegmental area in
rats. Brain Res. Bull. 15, 537–538. doi: 10.1016/0361-9230(85)90048-6
Jennes, L., Stumpf, W. E., and Kalivas, P. W. (1982). Neurotensin: topographical
distribution in rat brain by immunohistochemistry. J. Comp. Neurol. 210,
211–224. doi: 10.1002/cne.902100302
Johnson, S. W., and North, R. A. (1992). Two types of neurone in the rat
ventral tegmental area and their synaptic inputs. J. Physiol. 450, 455–468. doi:
10.1113/jphysiol.1992.sp019136
Jolicoeur, F. B., St-Pierre, S., Aubé, C., Rivest, R., and Gagné, M. A. (1984).
Relationships between structure and duration of neurotensin’s central action:
emergence of long acting analogs.Neuropeptides 4, 467–476. doi: 10.1016/0143-
4179(84)90090-8
Kalivas, P.W., Nemeroff, C. B., and Prange, A. J. Jr. (1981). Increase in spontaneous
motor activity following infusion of neurotensin into the ventral tegmental
area. Brain Res. 229, 525–529. doi: 10.1016/0006-8993(81)91016-7
Kalivas, P. W., Nemeroff, C. B., and Prange, A. J. Jr. (1984). Neurotensin
microinjection into the nucleus accumbens antagonizes dopamine-induced
increase in locomotion and rearing. Neuroscience 11, 919–930.
Kalivas, P. W., Richardson-Carlson, R., and Duffy, P. (1986). Neuromedin N
mimics the actions of neurotensin in the ventral tegmental area but not in the
nucleus accumbens. J. Pharmacol. Exp. Ther. 238, 1126–1131.
Kalivas, P. W., and Taylor, S. (1985). Behavioral and neurochemical effect of daily
injection with neurotensin into the ventral tegmental area. Brain Res. 358,
70–76. doi: 10.1016/0006-8993(85)90949-7
Kempadoo, K. A., Tourino, C., Cho, S. L., Magnani, F., Leinninger, G. M., Stuber,
G. D., et al. (2013). Hypothalamic neurotensin projections promote reward by
enhancing glutamate transmission in the VTA. J. Neurosci. 33, 7618–7626. doi:
10.1523/JNEUROSCI.2588-12.2013
Kinkead, B., and Nemeroff, C. B. (2002). Neurotensin: an endogenous
antipsychotic? Curr. Opin. Pharmacol. 2, 99–103. doi: 10.1016/S1471-
4892(01)00128-X
Kitabgi, P., Poustis, C., Granier, C., Van, R. J., Rivier, J., Morgat, J. L., et al.
(1980). Neurotensin binding to extraneural and neural receptors: comparison
with biological activity and structure–activity relationships. Mol. Pharmacol.
18, 11–19.
Labbé-Jullié, C., Dubuc, I., Brouard, A., Doulut, S., Bourdel, E., Pelaprat, D.,
et al. (1994). In vivo and in vitro structure-activity studies with peptide and
pseudopeptide neurotensin analogs suggest the existence of distinct central
neurotensin receptor subtypes. J. Pharmacol. Exp. Ther. 268, 328–336.
Lacey, M. G., Mercuri, N. B., and North, R. A. (1989). Two cell types in rat
substantia nigra zona compacta distinguished by membrane properties and the
actions of dopamine and opioids. J. Neurosci. 9, 1233–1241.
Leonetti, M., Brun, P., Clerget, M., Steinberg, R., Soubrié, P., Renaud, B., et al.
(2004). Specific involvement of neurotensin type 1 receptor in the neurotensin-
mediated in vivo dopamine eﬄux using knock-out mice. J. Neurochem. 89, 1–6.
doi: 10.1046/j.1471-4159.2003.02231.x
Leonetti, M., Brun, P., Sotty, F., Steinberg, R., Soubrié, P., Bert, L., et al.
(2002). The neurotensin receptor antagonist SR 142948A blocks the eﬄux
of dopamine evoked in nucleus accumbens by neurotensin ejection into the
ventral tegmental area. Naunyn Schmiedebergs Arch. Pharmacol. 365, 427–433.
doi: 10.1007/s00210-002-0574-6
Luo, Y., Good, C. H., Diaz-Ruiz, O., Zhang, Y., Hoffman, A. F., Shan, L., et al.
(2010). NMDA receptors on non-dopaminergic neurons in the VTA support
cocaine sensitization. PLoS ONE 5:e12141. doi: 10.1371/journal.pone.0012141
Margolis, E. B., Lock, H., Hjelmstad, G. O., and Fields, H. L. (2006).
The ventral tegmental area revisited: is there an electrophysiological
marker for dopaminergic neurons? J. Physiol. 577, 907–924. doi:
10.1113/jphysiol.2006.117069
Margolis, E. B., Toy, B., Himmels, P., Morales, M., and Fields, H. L. (2012).
Identification of rat ventral tegmental area GABAergic neurons. PLoS ONE
7:e42365. doi: 10.1371/journal.pone.0042365
Mazella, J., and Vincent, J. P. (2006). Functional roles of the NTS2 and NTS3
receptors. Peptides 27, 2469–2475. doi: 10.1016/j.peptides.2006.04.026
Mazella, J., Zsürger, N., Navarro, V., Chabry, J., Kaghad,M., Caput, D., et al. (1998).
The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled
receptor. J. Biol. Chem. 273, 26273–26276. doi: 10.1074/jbc.273.41.26273
Paxinos, G., and Watson, C. (1986). The Rat Brain in Stereotaxic Coordinates. New
York, NY: Academic Press.
Rompré, P. P. (1995). Psychostimulant-like effect of central microinjection
of neurotensin on brain stimulation reward. Peptides 16, 1417–1420. doi:
10.1016/0196-9781(95)02032-2
Rompré, P. P. (1997). Repeated activation of neurotensin receptors sensitizes to
the stimulant effect of amphetamine. Eur. J. Pharmacol. 328, 131–134. doi:
10.1016/S0014-2999(97)00159-3
Rompré, P. P., Bauco, P., and Gratton, A. (1992). Facilitation of brain stimulation
reward by mesencephalic injections of neurotensin-(1-13). Eur. J. Pharmacol.
211, 295–303. doi: 10.1016/0014-2999(92)90384-G
Rompré, P. P., and Gratton, A. (1992). A comparison of the effects of
mesencephalic injections of neurotensin(1-13) and neuromedin N on brain
electrical stimulation. Peptides 13, 713–719. doi: 10.1016/0196-9781(92)
90177-5
Rompré, P. P., and Gratton, A. (1993). Mesencephalic microinjections of
neurotensin-(1-13) and its C-terminal fragment, neurotensin-(8-13), potentiate
brain stimulation reward. Brain Res. 616, 154–162. doi: 10.1016/0006-
8993(93)90204-Z
Rostène, W. H., and Alexander, M. J. (1997). Neurotensin and neuroendocrine
regulation. Front. Neuroendocrinol. 18, 115–173. doi: 10.1006/frne.199
6.0146
Sarret, P., Gendron, L., Kilian, P., Nguyen, H. M., Gallo-Payet, N., Payet, M. D.,
et al. (2002). Pharmacology and functional properties of NTS2 neurotensin
receptors in cerebellar granule cells. J. Biol. Chem. 277, 36233–36243. doi:
10.1074/jbc.M202586200
Seutin, V., Massotte, L., and Dresse, A. (1989). Electrophysiological effects of
neurotensin on dopaminergic neurones of the ventral tegmental area of the rat
in vitro. Neuropharmacology 28, 949–954.
Shi, W. X., and Bunney, B. S. (1991). Effects of neurotensin on midbrain dopamine
neurons: are they mediated by formation of a neurotensin-dopamine complex?
Synapse 9, 157–164. doi: 10.1002/syn.890090302
Sicard, F., Contesse, V., Lefebvre, H., Ait-Ali, D., Gras, M., Cartier, D., et al.
(2006). The N-terminal fragment, NT1-11, inhibits cortisol secretion by
human adrenocortical cells. J. Clin. Endocrinol. Metab. 91, 3131–3137. doi:
10.1210/jc.2006-0105
Sotty, F., Brun, P., Leonetti, M., Steinberg, R., Soubrie, P., Renaud, B., et al.
(2000). Comparative effects of neurotensin, neurotensin(8-13) and [D-
Tyr(11)]neurotensin applied into the ventral tegmental area on extracellular
dopamine in the rat prefrontal cortex and nucleus accumbens.Neuroscience 98,
485–492. doi: 10.1016/S0306-4522(00)90023-X
Frontiers in Neuroscience | www.frontiersin.org 13 December 2015 | Volume 9 | Article 470
Rouibi et al. Neurotensin-Glutamate Interaction and Conditioned Reward
Spigelman, I., Zhang, L., and Carlen, P. L. (1992). Patch-clamp study of postnatal
development of CA1 neurons in rat hippocampal slices: membrane excitability
and K+ currents. J. Neurophysiol. 68, 55–69.
Steinberg, R., Brun, P., Fournier, M., Souilhac, J., Rodier, D., Mons, G.,
et al. (1994). SR48692, a non peptide neurotensin receptor antagonist
differentially affects neurotensin-induced behavior and changes in
dopaminergic neurotransmission. Neuroscience 59, 921–929. doi:
10.1016/0306-4522(94)90295-X
Steinberg, R., Brun, P., Souilhac, J., Bougault, I., Leyris, R., Le
Fur, G., et al. (1995). Neurochemical and behavioural effects of
neurotensin vs [D-Tyr11]neurotensin on mesolimbic dopaminergic
function. Neuropeptides 28, 43–50. doi: 10.1016/0143-4179(95)
90073-X
St-Gelais, F., Jomphe, C., and Trudeau, L. E. (2006). The role of neurotensin in
central nervous system pathophysiology: what is the evidence? J. Psychiatry
Neurosci. 31, 229–245.
Stowe, Z. N., Landry, J. C., Tang, Z., Owens, M. J., Kinkead, B., and Nemeroff, C. B.
(2005). The electrophysiological effects of neurotensin on spontaneously active
neurons in the nucleus accumbens: an in vivo study. Synapse 58, 165–172. doi:
10.1002/syn.20190
Tanaka, K., Masu, M., and Nakanishi, S. (1990). Structure and functional
expression of the cloned rat neurotensin receptor. Neuron 4, 847–854. doi:
10.1016/0896-6273(90)90137-5
Thibault, D., Albert, P. R., Pineyro, G., and Trudeau, L. É. (2011). Neurotensin
triggers dopamine D2 receptor desensitization through a protein kinase C
and beta-arrestin1-dependent mechanism. J. Biol. Chem. 286, 9174–9184. doi:
10.1074/jbc.M110.166454
Vincent, J. P., Mazella, J., and Kitabgi, P. (1999). Neurotensin and
neurotensin receptors. Trends Pharmacol. Sci. 20, 302–309. doi:
10.1016/S0165-6147(99)01357-7
Wagstaff, J. D., Bush, L. G., Gibb, J. W., and Hanson, G. R. (1994). Endogenous
neurotensin antagonizes methamphetamine-enhanced dopaminergic activity.
Brain Res. 665, 237–244. doi: 10.1016/0006-8993(94)91343-9
Woulfe, J., and Beaudet, A. (1989). Immunocytochemical evidence for direct
connections between neurotensin-containing axons and dopaminergic neurons
in the rat ventral midbrain tegmentum. Brain Res. 479, 402–406. doi:
10.1016/0006-8993(89)91649-1
Xiao, Z., Cilz, N. I., Kurada, L., Hu, B., Yang, C., Wada, E., et al. (2014). Activation
of neurotensin receptor 1 facilitates neuronal excitability and spatial learning
and memory in the entorhinal cortex: beneficial actions in an Alzheimer’s
disease model. J. Neurosci. 34, 7027–7042. doi: 10.1523/JNEUROSCI.0408-
14.2014
Zhang, H., Dong, H., and Lei, S. (2015). Neurotensinergic augmentation of
glutamate release at the perforant path-granule cell synapse in rat dentate
gyrus: roles of L-Type Ca channels, calmodulin and myosin light-chain kinase.
Neuropharmacology 95, 252–260. doi: 10.1016/j.neuropharm.2015.03.028
Zweifel, L. S., Argilli, E., Bonci, A., and Palmiter, R. D. (2008). Role of NMDA
receptors in dopamine neurons for plasticity and addictive behaviors. Neuron
59, 486–496. doi: 10.1016/j.neuron.2008.05.028
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Rouibi, Bose, Rompré and Warren. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 14 December 2015 | Volume 9 | Article 470
